CDK6 and small cell lung carcinoma: In addition, the RNA expression levels of cyclin D1 and CDK6 were significantly lower in the SCLC cell groups receiving first‐line therapy together with exosome pathway inhibitors than in the SCLC cell groups receiving cisplatin‐plus‐etoposide treatment and untreated groups (Figure 5D).